

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	4,642,100	4,822,600	4,989,600	5,148,600
Prediabetes	1,309,400	1,405,100	1,497,300	1,547,000
Diagnosed diabetes	418,800	515,300	599,500	667,900
Undiagnosed diabetes	139,000	162,500	179,300	189,300
Total with diabetes (diagnosed and undiagnosed)	557,800	677,800	778,800	857,200
Complications:				
Visual impairment	68,700	82,000	92,600	100,200
Renal failure	1,000	1,190	1,330	1,430
Leg amputations	870	980	1,050	1,080
Annual deaths attributable to diabetes	4,510	5,300	5,850	6,180
Total annual cost (2015 dollars)	\$6.0 B	\$7.3 B	\$8.4 B	\$9.2 B
Annual medical costs	\$4.5 B	\$5.5 B	\$6.3 B	\$6.9 B
Annual nonmedical costs	\$1.5 B	\$1.8 B	\$2.1 B	\$2.3 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	729,200	866,300	1,009,200	1,134,500
Prediabetes	371,900	441,800	514,700	578,600
Diagnosed diabetes	137,800	163,700	190,700	214,400
Undiagnosed diabetes	51,000	60,600	70,600	79,400
Total with diabetes (diagnosed and undiagnosed)	188,900	224,400	261,400	293,800
Complications:				
Visual impairment	25,800	29,800	33,900	37,100
Renal failure	420	490	550	600
Leg amputations	320	350	380	390
Annual deaths attributable to diabetes	3,110	3,550	3,800	3,890
Total annual cost (2015 dollars)	\$2.4 B	\$2.9 B	\$3.3 B	\$3.8 B
Annual medical costs	\$2.3 B	\$2.7 B	\$3.1 B	\$3.5 B
Annual nonmedical costs	\$0.1 B	\$0.2 B	\$0.2 B	\$0.3 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.